key: cord-1052314-wduwd1xk authors: Wolfe, Ian D.; Patel, Sameer J. title: SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations: SARS-CoV-2 Monoclonal Antibodies in Children date: 2021-05-06 journal: Clin Ther DOI: 10.1016/j.clinthera.2021.04.008 sha: 1b9e1ca49104a2bfc459931747aebda909691654 doc_id: 1052314 cord_uid: wduwd1xk Monoclonal antibodies have been approved under emergency use authorization for children with certain conditions at higher risk of developing severe COVID-19. There is no safety or efficacy data for these therapies in persons less than 18 years of age, there is risk. We don't know that they will work, but they could. A disproportionate number who meet criteria are from Black, Indigenous, and communities of color. How should health systems, hospitals, and clinicians balance the tensions between being seen as experimenting with an untested drug as opposed to withholding a potentially life-saving treatment? This paper will identify, analyze, and make recommendations on how health systems, hospitals, and individual clinicians can ethically balance these different tensions. Interim analysis of the BLAZE-1 study, an ongoing Phase II trial of the efficacy and safety of bamlanivimab and etesevimab in adults with recently diagnosed mild to moderate coronavirus disease 2019 in the outpatient setting, demonstrated reduction in progression to related hospitalizations. 1 Of participants who received bamlanivamb and eteseviamb combination therapy, only 0.9% required emergency department visits and hospitalization compared to 5.8% in the placebo group. 1 Similarly, an interim analysis of a trial of monoclonal antibody (mAb) 'cocktail' casirivimab and imdevimab (REGN-COV2), demonstrated reduction in subsequent COVID-19-related medically attended visits, 3% of those who received REGN-COV2 and 6% receiving the placebo. 2 While these findings are preliminary, and showed modest effect in reducing progression to severe disease, these drugs may be very beneficial for high risk patients and may reduce the burden on our healthcare system, particularly since other therapeutic options are limited. The emergency use authorization (EUA) was granted by the Food and Drug Administration (FDA) for both products to include children 12-17 years of age and greater than 40 kg. 3 The clinical eligibility criteria include several high-risk pediatric chronic conditions despite both agents lacking evidence for those <18 years of age. The Infectious Disease Society of America (IDSA) and the Pediatric Infectious Disease Society (PIDS) have recommended against the routine use of mAbs in children (but with consideration in individual cases for highrisk patients evidenced by pediatric-specific data), and the National Institutes of Health (NIH) has not made recommendation for or against its use in children due to insufficient data. 3, 4 These three organizations did not fully oppose the use of mAbs in children. This is a complex situation, and ethical considerations might differ between the federal, state, and hospital level. [5] [6] [7] States are allocating mAbs under the EUA (Figure 1 ) to treat 12-17-yearolds positive for and symptomatic with COVID-19 with no pediatric trial data, but with possible expected benefit. This brings up two important ethically challenging questions for health systems, hospitals, and clinicians: should a treatment tested exclusively in adults with preliminary data on safety and efficacy be given to children, and if so, how do you balance risk and benefit, equity and harm, while striving for trustworthiness? This paper will identify, analyze, and make recommendations around organizational and individual clinician obligations in offering mAb therapy to children for treatment of COVID-19. The EUA lists comorbidities eligible for mAbs in the 12-17-year-old age group ( Figure 1 ). Chronic conditions in children associated with COVID-19 hospitalization include technologydependence, obesity, immune suppression/malignancy, neurological disorders, cardiac disease, and chronic lung disease. 3, 4, 8, 9 However, pediatric reports have varied on the impact of these risk factors, limited by fewer patients and lower absolute risk than in adult studies. 6 Furthermore, many of the descriptors are vague. For example, technology dependence is a spectrum from intermittent use of a feeding pump to total dependance on a mechanical ventilator, and immune suppression encompasses a range of conditions. Diagnoses associated with hospital admission, such as respiratory failure, may not reflect COVID-19 severity, as COVID-19 diagnosis may not be the primary driver of hospitalization for children with chronic medical conditions. It may be difficult to distinguish disease progression or complication from COVID-19 severity. Thus, risk stratification for progression to severe disease is inherently difficult in children. It is unclear how the perceived benefit of mAbs for children were balanced with the risks. A national clinical trial would be ideal to assure adequate patient protections, safety, equitable access, and informed consent. Absent this, hospitals and state departments of health will have to carefully balance the tensions between risk and benefit. Children's hospitals or entities who will be distributing and administering mAb therapy to eligible children are confronted by a difficult decision whether to participate. Children do not progress to severe disease as often as adults, but serious morbidity and mortality is possible, and thus potential individual and community benefit exists. It would be reasonable to not participate from an ethical stance given the lack of data in children, the potential for harm, and the IDSA, PIDS, and NIH positions; the risks and burdens may outweigh the benefits in some areas. New and innovative therapies require a delicate balance between beneficence and non-maleficence. If a hospital takes the stance that mAbs should not be given to children due insufficient benefit over risk then they have no ethical obligation to refer elsewhere and must make this stance known to their respective departments of health. However, there are likely some patients are followed by pediatric specialists who are over 18 years of age and might benefit, and efforts to assist these patients in gaining access to mAbs should be made. There are also many logistical challenges. 3 Infusion centers will need to be set up, requiring physical and technological resources. Children receiving mAbs will need to be fully, assessed, including a medical history and physical exam. If primary medical systems choose not to participate, some children who might benefit and wish to receive a mAb will have to go to an unfamiliar institution. Administration requires a facility capable of safely monitoring pediatric patients during and after infusion and responding to any potential adverse reactions, including anaphylaxis. As mAbs are funded and allocated through federal and state public health agencies, children may be referred from other facilities or regions, full medical records may not be available. Adherence to distancing and mitigation strategies will be challenging. COVID-19 positive children will be accompanied by parents or guardians who are also likely infected or exposed. Given the amount resources this will require, the lack of data in children, and the documented benefit for mAbs in the adult population, it would be reasonable to choose not to allocate them to children at all. If these challenges preclude a hospital from participating in allocation despite belief in some benefit for children, then they are obligated to consider whether this decision will prohibit access for their pediatric patient populations, particularly if other centers are not offering infusion for children. Given the disparate effects of COVID-19 on certain communities there may need to be a consideration to justice. While Hispanic and Black children make up 25% and14% of the US child population respectively, and White children 50%, 10 11 This trend is similar to results published in 2020. 12 If a hospital chooses to participate in allocation it has an obligation to not only their patients but also an obligation to their state department of health, who is trusting them to allocate mAbs to the public. This requires hospitals to consider a unique set of duties, notably, whether an individual clinician within the hospital has a duty to offer it (patient-provider relationship), and whether they should strictly adhere to the EUA which may not represent the actual population of children progressing to severe illness (hospital-community relationship). Clinicians are never ethically obligated to provide a treatment that is not standard. However, as with other recommendations to prevent and treat COVID-19 during the pandemic, standards of therapy have rapidly evolved, and have a lower burden of scientific proof than normal. When there are questions around benefits, and reasonable people might choose either option, it becomes the obligation of clinicians to provide adequate information on risk and benefit and the context on how this was determined for their child, make a recommendation, but ultimately respect parents' decision. It becomes the ethical obligation of the clinician to assist the family in understanding the decision (transparency). This includes knowledge of the study and its limitations and what an EUA means. The reason for transparency is not only ethical but practical. In the context of an EUA without data in children, mAbs may appear to be experimental in the eyes of patients and parents. Given the lack of data on safety and efficacy in children, there is an important tension between using an unproven, but potentially beneficial therapy (innovation), and withholding it from those that might benefit (exclusion). Improperly balancing or lack of appreciation of this tension will lead to a hospital and its clinicians to be viewed as untrustworthy. On one side of this tension, a hospital might appear as experimenting in populations that historically have lower trust in medical and scientific institutions due to a long history of racism, abuse, and mistreatment. COVID-19 hospitalizations and the chronic medical conditions in the mAb EUA criteria, disproportionately affect Black, Native, and Hispanic children. Yet while Hispanic patients were 43% of the BLAZE-1 subjects and 56% in the REGN-COV2 trial, Black patients made up roughly 7% and 13% respectively. 1,2 On the opposite side of the tension, a hospital could be seen as being exclusionary if it denies minority populations the choice of a beneficial therapy, or if it is distributed inequitably. To balance this tension, transparency emerges as the prima facie obligation to meet a hospital's duty of trustworthiness. 13 A hospital must be transparent about the limitations in data available. When families are scared and information is being disseminated rapidly-and not always reliably or easy to comprehend-hospitals must manage this and be steadfast in their dedication to assuring appropriate transparent consideration of data around treatments. Clinicians must provide knowledge and recommendations individual to each patient consistent with shared decision-making norms. Clinical eligibility for mAbs in pediatrics must be developed not solely off the EUA but supplemented with systematically collected data from within each organization or region on which 12-17-year-olds are progressing to severe disease, what the common comorbidities are, and who will most likely benefit. Eligibility criteria, education, and outreach should prioritize minority communities, which have borne the brunt of the COVID-19 epidemic. If a children's hospital chooses to allocate a mAb to the community, it is as a public resource and it must be offered to all children who fit carefully thought out eligibility criteria developed specifically for the pediatric population most likely to benefit, and ideally in conjunction with other pediatric facilities in the state. This may seem intrusive to the individual duty a clinician feels to their patient, and a clinician's professional autonomy. Clinician's may feel conflicted given the lack of efficacy and safety data. This is reasonable. But their obligations have not disappeared. Clinicians should offer their opinion and recommendation to families, weigh the risks and benefits for each child, even if they advise parents against it. Another option that is more burdensome is to convene ad hoc discussions between specialists and primary clinicians to determine the benefit and risk prior to offering a mAb. Absent a national pediatric clinical trial in conjunction with allocation, hospitals and departments of health should treat mAb infusions for COVID-19 as a clinical trial in order to assure ethically acceptable patient safety, access, and informed consent. Parental concerns around their child progressing to severe disease creates a potential power shift and hospitals and clinicians must consider this, assure they have scrutinized the EUA criteria to meet their ethical and clinical obligation to patients in conjunction with their departments of health to ensure consistency with other pediatric infusion centers. Given the broad criteria of the EUA, health systems and children's hospitals should convene workgroups to further clarify eligibility criteria. Discussion between specialists may be needed for each patient to assess risks and benefits. Criteria should be tailored through institutional or regional clinical data. Once the criteria is set, mAbs must be offered equally to all patients meeting criteria but with an equitable amount of time for the shared decision-making process with their individual clinician. There is a clear lack of safety and efficacy data around mAbs in children, a likely high number needed to treat and an important consideration to risk of more harm from untested therapies than from COVID-19 itself in the pediatric population. There may be a reasonable public health utilitarian argument for diverting all mAb supplies to the adult populations given the likely higher benefit especially is supply becomes limited. It appears that an amount is held specifically for allocation to children's hospitals, however the guidance from the National Governors Association has not addressed this. 14 Orders for mAbs are done through the Federal government and utilization data is required and subsequent orders are subject to previous orders and utilization. 15 Scarce resources should generally maximize benefit, however there does not appear to be a limited supply of mAbs so far, possibly in part due to a low demand, and so this argument is currently ethically unsupportable. 16 When offering mAb therapy to children, pediatric providers will likely identify parents or grandparents with concurrent COVID and high-risk conditions. Certainly some of those adults will be eligible for mAb therapy, and may have language, socioeconomic, or racially constructed barriers of access to care. To address this ethical concern, formal processes should be developed to refer ill family members to adult providers. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 COVID-19 Real-Time Learning Network: Monoclonal Antibodies. Idsociety.org. Updated Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents The Ethics of Creating a Resource Allocation Strategy During the COVID-19 Pandemic Fair allocation of scarce medical resources in the time of Covid-19 Fairly prioritizing groups for access to COVID-19 vaccines Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities What the Data Say About Race VPS. COVID-19 Data: North American Pediatric ICUs. Covid19.myvps.org. Updateed daily. Accessed The impact of coronavirus disease 2019 pandemic on US and Canadian PICUs COVID19: Why justice and transparency in hospital triage policies are paramount Antibody Therapies For COVID-19: What Governors Need To Know Overview of Direct Order Process for COVID-19 Therapeutics Allocation of Casirivimab/Imdevimab by Jursidiction Trust in Health Care in the Time of COVID-19 Hospitals and clinicians need to move away from asking why certain populations don't trust them and towards striving to be trustworthy. 17 Monoclonal antibodies pose a difficult balance for children's hospitals balancing competing priorities in trying to do what is best for children.